tbuckley/cabot-search huggingface dataset:
Hormone Therapy and Menopausal Symptoms Among Women Participating in a Behavioral Lifestyle Intervention: The Women’s Healthy Lifestyle Project
Authors: Miriam A. Boraz, Laurey R Simkin-Silverman, Rena R. Wing, Elaine N. Meilahn, Lewis H. Kuller
Journal: Circulation (2001)

P91     The decision to take hormone replacement therapy (HRT) is a  choice many women encounter when entering menopause. In light of  controversy of the benefits and risks of HRT use, an important question  to ask is on what basis are women taking HRT, and are they taking  hormone therapy because they are at higher risk. The purpose of this  study was to examine HRT use in women who are participating in a  behavioral lifestyle intervention through the menopause. The Women’s  Healthy Lifestyle Project (WHLP) was a 5-year randomized clinical trial  designed to examine whether a behavioral lifestyle intervention could  decrease the expected rise in cardiovascular risk through the  menopause. A sample of 535 healthy premenopausal women, aged 44-50  years (M=47 + 1.9) participated in the study. The intervention was  highly successful in buffering risk elevation through the 54-month  visit. The control group gained 5.2 lb over the 54 month study and the  intervention group remained 0.18 lb below baseline (p=.00). The  intervention group’s LDLc increased by 3.5 mg/dl, and the control  group’s LDLc increased by 8.9 mg/dl (p=.01). At the 54-month visit,  there was no difference between the intervention and control groups in  menopausal status, with 34.7% of the women postmenopausal. There was  no difference between intervention and control groups with regard to  HRT use, with 31.2% of the total sample reporting use of HRT. Further,  there was no difference in menopausal symptoms between treatment  groups. The women started HRT an average of 6 months after they missed  a period. Analysis was done to examine predictors of HRT use in this  group of women. Baseline cardiovascular risk factors did not predict  HRT use at the 54-month visit. Moreover, the number of menopausal  symptoms did not predict HRT use at 54 months. There was little  difference between the women who were taking HRT and the women who were  not taking HRT. There was a high use of HRT in this group of healthy,  well-educated women. But an intensive lifestyle intervention did not  change the use of HRT.
Breastfeeding during infancy and neurocognitive function in adolescence: 16-year follow-up of the PROBIT cluster-randomized trial
Authors: Seungmi Yang, Richard M. Martin, Emily Oken, Mikhail Hameza, Glen Doniger, Shimon Amit, Rita Patel, Jennifer Thompson, Sheryl L. Rifas-Shiman, Konstantin Vilchuck, Natalia Bogdanovich, Michael S. Kramer
Journal: PLoS Medicine (2018)

Background Evidence on the long-term effect of breastfeeding on neurocognitive development is based almost exclusively on observational studies. In the 16-year follow-up study of a large, cluster-randomized trial of a breastfeeding promotion intervention, we evaluated the long-term persistence of the neurocognitive benefits of the breastfeeding promotion intervention previously observed at early school age. Methods and findings A total of 13,557 participants (79.5% of the 17,046 randomized) of the Promotion of Breastfeeding Intervention Trial (PROBIT) were followed up at age 16 from September 2012 to July 2015. At the follow-up, neurocognitive function was assessed in 7 verbal and nonverbal cognitive domains using a computerized, self-administered test battery among 13,427 participants. Using an intention-to-treat (ITT) analysis as our prespecified primary analysis, we estimated cluster- and baseline characteristic-adjusted mean differences between the intervention (prolonged and exclusive breastfeeding promotion modelled on the Baby-Friendly Hospital Initiative) and control (usual care) groups in 7 cognitive domains and a global cognitive score. In our prespecified secondary analysis, we estimated mean differences by instrumental variable (IV) analysis to account for noncompliance with the randomly assigned intervention and estimate causal effects of breastfeeding. The 16-year follow-up rates were similar in the intervention (79.7%) and control groups (79.3%), and baseline characteristics were comparable between the two. In the cluster-adjusted ITT analyses, children in the intervention group did not show statistically significant differences in the scores from children in the control group. Prespecified additional adjustment for baseline characteristics improved statistical precision and resulted in slightly higher scores among children in the intervention for verbal function (1.4 [95% CI 0.3–2.5]) and memory (1.2 [95% CI 0.01–2.4]). IV analysis showed that children who were exclusively breastfed for ≥3 (versus <3) months had a 3.5-point (95% CI 0.9–6.1) higher verbal function, but no differences were observed in other domains. While our computerized, self-administered cognitive testing reduced the cluster-level variability in the scores, it may have increased individual-level measurement errors in adolescents. Conclusions We observed no benefit of a breastfeeding promotion intervention on overall neurocognitive function. The only beneficial effect was on verbal function at age 16. The higher verbal ability is consistent with results observed at early school age; however, the effect size was substantially smaller in adolescence. PROBIT trial registration ClinicalTrials.gov NCT01561612
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Authors: Ahmed A. Mohamed, Charles P. Xavier, Gauthaman Sukumar, Shyh-Han Tan, Lakshmi Ravindranath, Nishat Seraj, Vineet Kumar, Taduru Sreenath, David G. McLeod, Gyorgy Petrovics, Inger L. Rosner, Meera Srivastava, Jeffrey Strovel, Sanjay V. Malhotra, Nicole A. LaRonde, Albert Dobi, Clifton L. Dalgard, Shiv Srivastava
Journal: Cancer Research (2018)

Oncogenic activation of the ETS-related gene (ERG) by recurrent gene fusions (predominantly TMPRSS2-ERG) is one of the most validated and prevalent genomic alterations present in early stages of prostate cancer. In this study, we screened small-molecule libraries for inhibition of ERG protein in TMPRSS2-ERG harboring VCaP prostate cancer cells using an In-Cell Western Assay with the highly specific ERG-MAb (9FY). Among a subset of promising candidates, 1-[2-Thiazolylazo]-2-naphthol (NSC139021, hereafter ERGi-USU) was identified and further characterized. ERGi-USU selectively inhibited growth of ERG-positive cancer cell lines with minimal effect on normal prostate or endothelial cells or ERG-negative tumor cell lines. Combination of ERGi-USU with enzalutamide showed additive effects in inhibiting growth of VCaP cells. A screen of kinases revealed that ERGi-USU directly bound the ribosomal biogenesis regulator atypical kinase RIOK2 and induced ribosomal stress signature. In vivo, ERGi-USU treatment inhibited growth of ERG-positive VCaP tumor xenografts with no apparent toxicity. Structure-activity-based derivatives of ERGi-USU recapitulated the ERG-selective activity of the parental compound. Taken together, ERGi-USU acts as a highly selective inhibitor for the growth of ERG-positive cancer cells and has potential for further development of ERG-targeted therapy of prostate cancer and other malignancies.Significance: A highly selective small-molecule inhibitor of ERG, a critical driver of early stages of prostate cancer, will be imperative for prostate cancer therapy. Cancer Res; 78(13); 3659-71. ©2018 AACR.
Blood products as source of HEV transmission? 1-year experience with routine HEV screening at a tertiary center
Authors: T. Horvatits, D. Westhölter, J. Hiller, U. Denzer, P. Sven, S. Polywka, A. Lohse, S. Pischke, M. Luetgehmann
Journal: Journal of Hepatology (2018)
Pulmonary hypertension: Real-world data from a Portuguese expert referral centre
Authors: A. Gomes, C. Cruz, J. Rocha, M. Ricardo, M. Vicente, A. Melo, M. Santos, L. Carvalho, F. Gonçalves, A. Reis
Journal: Pulmonology (2018)

Pulmonary hypertension (PH) is a heterogeneous, debilitating condition with highly relevant impact on functional capacity, quality of life, and life-expectancy. This study aims to provide long-term data on the Portuguese PH population, by characterising the clinical presentation, evolution, and outcomes of PH patients in a specialised referral centre. Retrospective analysis of a cohort of 101 patients with pre-capillary PH (pcPH) referenced to an expert tertiary care referral centre in northern Portugal from 2002 to 2013. Diagnosis was confirmed by right heart catheterisation (RHC). PH classification followed consensus criteria from the 5th World Symposium in Nice, 2013. The most frequent causes of pcPH were Group 1 PH – pulmonary arterial hypertension (PAH) (54.4%) and Group 4 PH – Chronic thromboembolic pulmonary hypertension (CTEPH) (25.7%); importantly, 17.8% of patients presented PH associated with multiple aetiologies. Targeted therapy was used in 91.1% of patients (48.5% combination therapy). 1-, 3-, and 5-year survival was estimated at 86.6%, 76.7%, and 64.1%, respectively. Survival was significantly better for those ≤40 years old (10.5 vs. 6.4 years; P = 0.003) and for women with I/HPAH (9.3 vs. 4.5 years; P = 0.039). This study provides long-term, real-world data for the management of PAH and CTEPH in Portugal and demonstrates the importance of dedicated electronic medical records and well defined clinical management protocols for better patient outcomes. Patients presented mostly with intermediate or high risk of mortality, which suggests delayed diagnosis and highlights the need to increase awareness among clinicians.
Improving the Propranolol Treatment of Melanoma—Reply
Authors: Silvia Benemei, Pierangelo Geppetti, Vincenzo De Giorgi
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 12645: Coronary Sinus Biomarker Assessments in Non-ST Elevation Acute Coronary Syndrome: Systemic or Local Cardiac Release of High Sensitivity C-Reactive Protein?
Authors: Sander A Damen, Gilbert E Cramer, Wim R Aengevaeren, Ton J Oude Ophuis, Marion J Fokkert, Lambert D Dikkeschei, Hendrik-Jan Dieker, Helmut Gehlmann, Freek W Verheugt, Harry Suryapranata, Marc A Brouwer
Journal: Circulation (2016)

Introduction: High sensitivity C-reactive protein (hsCRP) is frequently elevated in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). However, controversy remains regarding the origin of hsCRP. Reported theories vary from a systemic increase in inflammatory status, to a more local process. Purpose: To assess concentrations of hsCRP in patients with ongoing NSTE-ACS using multiple sampling sites, to enable measurement of systemic or local changes. Methods: 46 Troponin positive NSTE-ACS patients with significant coronary artery disease were included. Systemic arterial and venous blood was obtained, and right sided catheterization was performed to sample blood from the coronary venous system (CVS). In suitable patients, an additional blood sample was collected from the culprit coronary artery distal to the culprit lesion. Six hours post procedure blood was obtained from the systemic venous circulation. hsCRP concentrations were compared between the sampling sites. Results: The median hsCRP concentrations in the systemic arterial and venous blood were high and not significantly different. hsCRP concentrations in the CVS were significantly lower (table).The median hsCRP concentrations between blood collected from the culprit coronary artery distal to the culprit lesion and the systemic arterial circulation were not significantly different (4.56mg/L to 4.40mg/L, respectively, n=14; p=0.551). Systemic hsCRP concentrations six hours post procedure were significantly higher (5.66mg/L vs 4.86mg/L; p&lt;0.001). Conclusion: In this series of patients with ongoing NSTE-ACS a decrease in hsCRP from the systemic circulation to the CVS was observed. This observation, combined with similar concentrations proximal and distal to the culprit and higher systemic concentrations six hours post procedure favors an extracardiac source of hsCRP.
Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier
Authors: Alessia Alunno, Paul Studenic, Dieter Wiek, Petra Balážová, Daniel Aletaha
Journal: Annals of the Rheumatic Diseases (2018)

We have read with great interest the article by Redeker et al 1 investigating the determinants of psychological well-being in axial spondyloarthritis (SpA). The authors observed that among 1736 patients aged 18–79 years, 68% of subjects displayed depressive symptoms, ranging from mild to severe according to the five-item WHO Well-Being Index. This article clearly points out the burden of depressive symptoms in patients with SpA and its correlation with disease activity, functional impairment and other parameters including younger age. The authors emphasise that a potential explanation for the negative association between depressive symptoms and age might be a better capability to cope with the disease of adult compared with young patients. This aspect prompted our reflections, as the psychological impact of rheumatic and musculoskeletal diseases (RMDs) in young people is a major unmet need.

We previously reported that over 90% of young patients with RMDs outline an impact of their condition on mental health which, …
Margaret McCartney: A new era of consumerist private GP services
Authors: Margaret McCartney
Journal: BMJ (2018)

Where does the NHS stop and private healthcare start? Becoming a patient of a “private GP” used to involve registering wholesale. They would require an annual subscription, along with additional fees for consultations, home visits, prescriptions, and referrals. The division was marked not just by better carpets, furniture, and postcodes: the private sector was a separate sector.

We are now on a fuzzy edge that is quickly dissolving into a catastrophic fuddle. Dozens of private GP services now offer consultations for a fee, from £10 and usually under £50. These are an add-on to your NHS care, which you can use to skip a queue and prioritise yourself. Consultations are rapid, online, and …
Limitations of the National Cancer Data Base to Evaluate Early-Stage Anal Cancer Treatment Outcomes
Authors: Ira L. Leeds, Sandy H. Fang
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis
Authors: T. Dias, A. Santos, J. Carvalho, M. Bento-Miranda, M. Sant’anna, F. Calinas, R. Loureiro, A. Martins, G. Alexandrino, I. Cotrim, C. Martins, J. Presa, M. Mesquita, J. Nunes, A. Ferreira, A. Horta e Vale, A.L.C. Alves, I. Pedroto, L. Maia, A. Banhudo, I. Mocanu, A.M. Laranjo, S. Lopes, R. Liberal, C. Fonseca, J. Oliveira, M. Gomes, H. Cortez-Pinto
Journal: Journal of Hepatology (2018)
Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer
Authors: N. Mani, A.H.L. Li, A. Ardzinski, L. Bailey, J.R. Phelps, R. Burns, T. Chiu, A.G. Cole, A. Cuconati, B.D. Dorsey, E. Evangelista, D. Gotchev, T.O. Harasym, A. Jarosz, S. Kadhim, A. Kondratowicz, S.G. Kultgen, K. Kwak, A.C.H. Lee, S. Majeski, K. Mcclintock, J. Pan, C. Pasetka, R. Rijnbrand, A. Shapiro, H.M. Steuer, K. Stever, S. Tang, X. Teng, M. Wong, M.J. Sofia
Journal: Journal of Hepatology (2018)
Long-term associations between non-high density Lipoprotein Cholesterol and Apolipoprotein B in young adulthood and subclinical atherosclerosis in persons with nonalcoholic fatty liver disease in middle age: the CARDIA study
Authors: L. Vanwagner, J. Wilkins, H. Ning, N. Allen, J. Siddique, C. Lewis, N. Terrault, J.J. Carr, M. Rinella, D. Lloyd-Jones
Journal: Journal of Hepatology (2018)
Risk-stratified management of advanced hepatocellular carcinoma (HCC)
Authors: D.J. Pinato, D.E. Kaplan, C. Yen, L. Rimassa, B. Dominik, T. Pressiani, R. Thimme, M. Pirisi, M. Burlone, T. Arizumi, M. Kudo, J.W. Park, T.H. Taddei, P. Johnson, R. Sharma
Journal: Journal of Hepatology (2018)
Protein carbamylation exacerbates vascular calcification
Authors: Daisuke Mori, Isao Matsui, Akihiro Shimomura, Nobuhiro Hashimoto, Ayumi Matsumoto, Karin Shimada, Satoshi Yamaguchi, Tatsufumi Oka, Keiichi Kubota, Sayoko Yonemoto, Yusuke Sakaguchi, Atsushi Takahashi, Yasunori Shintani, Seiji Takashima, Yoshitsugu Takabatake, Takayuki Hamano, Yoshitaka Isaka
Journal: Kidney International (2018)
Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus
Authors: Elaine Kunzler, Linda S. Hynan, Benjamin F. Chong
Journal: JAMA Dermatology (2018)

Increased rates of autoimmune conditions have been reported in association with systemic lupus erythematosus (SLE). Little is known about coexisting autoimmune conditions in patients with cutaneous lupus erythematosus (CLE) without SLE.To determine the prevalence and risk factors of having coexisting autoimmune conditions in patients with CLE.This cross-sectional study was performed from November 2008 to February 2017 at the University of Texas Southwestern Medical Center (UTSW) and Parkland Health and Hospital System, Dallas, Texas. Participants were identified through the UTSW Cutaneous Lupus Registry. All participants had a dermatologist-confirmed diagnosis of CLE using clinicopathological correlation. Exclusion criteria included age younger than 18 years, and meeting at least 4 American College of Rheumatology diagnostic criteria for SLE. Participants with CLE and without concomitant autoimmune diseases were compared by demographic and disease characteristics.The primary and secondary outcomes were presence of coexisting autoimmune condition(s) and individual autoimmune diseases, respectively. Predictor variables significantly associated with coexisting autoimmune diseases were identified by univariate and multivariable logistic regression analyses.Among the 285 participants initially screened, 129 participants with CLE were included (102 [79.1%] female; median age, 49 years [interquartile range, 38.3-57.1 years]). Coexisting autoimmune conditions were found in 23 (17.8%). Autoimmune thyroid disease had the highest frequency at 4.7% (n = 6). Multivariable logistic regression analyses showed that patients with CLE who were white (odds ratio [OR], 2.88; 95% CI, 1.00-8.29; P = .0498), never smokers (OR, 3.28; 95% CI, 1.14-9.39; P = .03), had family history of autoimmune disease (OR, 3.54; 95% CI, 1.21-10.39; P = .02), and history of positive antinuclear antibody test result (OR, 4.87; 95% CI, 1.69-14.03; P = .003) had a significant association with having coexisting autoimmune conditions.This study suggests that patients with CLE without concurrent SLE can have increased rates of coexisting autoimmune conditions. Collecting a thorough review of systems can prompt clinicians to pursue further testing and evaluation by other specialists. Future studies investigating development of coexisting autoimmune conditions over time in the CLE population are necessary to confirm these findings.
Iatrogenic Infertility After Curative Stem Cell Transplantation in Patients With Sickle Cell Disease
Authors: Adrienne D. Mishkin, Markus Y. Mapara, Ran Reshef
Journal: Annals of Internal Medicine (2018)

Allogeneic hematopoietic stem cell transplantation (HSCT), the only known cure for sickle cell disease, involves pretransplantation regimens (alkylating agents and radiation) that may cause sterili...
ESRD among Immigrants to Ontario, Canada: A Population-Based Study
Authors: Jeffrey Perl, Eric McArthur, Vivian S. Tan, Danielle M. Nash, Amit X. Garg, Ziv Harel, Alvin H. Li, Manish M. Sood, Joel G. Ray, Ron Wald
Journal: Journal of the American Society of Nephrology (2018)

Background The epidemiology of ESRD requiring maintenance dialysis (ESRD-D) in large, diverse immigrant populations is unclear.Methods We estimated ESRD-D prevalence and incidence among immigrants in Ontario, Canada. Adults residing in Ontario in 2014 were categorized as long-term Canadian residents or immigrants according to administrative health and immigration datasets. We determined ESRD-D prevalence among these adults and calculated age-adjusted prevalence ratios (PRs) comparing immigrants to long-term residents. Among those who immigrated to Ontario between 1991 and 2012, age-adjusted ESRD-D incidence was calculated by world region and country of birth, with immigrants from Western nations as the referent group.Results Among 1,902,394 immigrants and 8,860,283 long-term residents, 1700 (0.09%) and 8909 (0.10%), respectively, presented with ESRD-D. Age-adjusted ESRD-D prevalence was higher among immigrants from sub-Saharan Africa (PR, 2.17; 95% confidence interval [95% CI], 1.84 to 2.57), Latin America and the Caribbean (PR, 2.11; 95% CI, 1.90 to 2.34), South Asia (PR, 1.45; 95% CI, 1.32 to 1.59), and East Asia and the Pacific (PR, 1.34; 95% CI, 1.22 to 1.46). Immigrants from Somalia (PR, 4.18; 95% CI, 3.11 to 5.61), Trinidad and Tobago (PR, 2.88; 95% CI, 2.23 to 3.73), Jamaica (PR, 2.88; 95% CI, 2.40 to 3.44), Sudan (PR, 2.84; 95% CI, 1.53 to 5.27), and Guyana (PR, 2.69; 95% CI, 2.19 to 3.29) had the highest age-adjusted ESRD-D PRs relative to long-term residents. Immigrants from these countries also exhibited higher age-adjusted ESKD-D incidence relative to Western Nations immigrants.Conclusions Among immigrants in Canada, those from sub-Saharan Africa and the Caribbean have the highest ESRD-D risk. Tailored kidney-protective interventions should be developed for these susceptible populations.
Immune response-eliciting exposure to Campylobacter vastly exceeds the incidence of clinically overt campylobacteriosis but is associated with similar risk factors: A nationwide serosurvey in the Netherlands
Authors: Susana Monge, Peter Teunis, Ingrid Friesema, Eelco Franz, Wim Ang, Wilfrid van Pelt, Lapo Mughini-Gras
Journal: Journal of Infection (2018)